Mahesh Patel Buys 25,000 Shares of Lipocine (NASDAQ:LPCN) Stock

Lipocine Inc. (NASDAQ:LPCN) CEO Mahesh Patel purchased 25,000 shares of the business’s stock in a transaction on Monday, April 6th. The shares were bought at an average price of $2.03 per share, for a total transaction of $50,750.00. Following the acquisition, the chief executive officer owned 160,679 shares in the company, valued at $326,178.37. This trade represents a 18.43% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Lipocine Price Performance

LPCN stock traded down $0.11 during mid-day trading on Monday, reaching $1.94. The company had a trading volume of 2,564,708 shares, compared to its average volume of 470,773. The firm has a fifty day simple moving average of $8.10 and a 200 day simple moving average of $5.78. Lipocine Inc. has a fifty-two week low of $1.81 and a fifty-two week high of $12.37.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.26. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.The business had revenue of $1.15 million during the quarter, compared to the consensus estimate of $0.12 million.

Hedge Funds Weigh In On Lipocine

Several hedge funds have recently added to or reduced their stakes in LPCN. Squadron Capital Management LLC acquired a new stake in Lipocine during the fourth quarter worth approximately $4,256,000. Diadema Partners LP acquired a new position in shares of Lipocine in the 4th quarter valued at $2,095,000. Ikarian Capital LLC purchased a new position in shares of Lipocine in the 4th quarter valued at $1,602,000. Persistent Asset Partners Ltd purchased a new position in shares of Lipocine in the 4th quarter valued at $567,000. Finally, Geode Capital Management LLC raised its stake in Lipocine by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after acquiring an additional 1,374 shares in the last quarter. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research report on Friday, March 27th. HC Wainwright reaffirmed a “neutral” rating on shares of Lipocine in a research report on Monday. Finally, Wall Street Zen upgraded shares of Lipocine from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $15.00.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.